How is bromocriptine mesylate (Cycloset) used in the treatment of type 2 diabetes mellitus (DM)?

Updated: Jul 13, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

In 2009, the FDA approved a quick-release formulation of bromocriptine mesylate (Cycloset) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Bromocriptine is a centrally acting dopamine D2 receptor agonist. When given in a single timed morning dose, it is thought to act on circadian neuronal activities within the hypothalamus to reset the abnormally elevated drive for increased plasma glucose, triglyceride, and free fatty acid levels in fasting and postprandial states in insulin-resistant patients. [278]

Quick-release bromocriptine may be considered for obese patients who do not tolerate other diabetes medications or who need only a minimal reduction in HbA1c to reach their glycemic goal. This agent has the benefits of not causing hypoglycemia and weight gain. In addition, a randomized trial of bromocriptine in 3095 patients found that cardiovascular events were less frequent in the treatment arm than in the placebo arm. [279]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!